Olmesartan/amlodipine: a review of its use in the management of hypertension.

Short Term Safety and Tolerability of a Fixed Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide. J Clin Diagn Res (2015) 0.88

Hypertension: Synergy of antihypertensives in elderly patients with CKD. Nat Rev Nephrol (2012) 0.77

Phototransformation of amlodipine: degradation kinetics and identification of its photoproducts. PLoS One (2014) 0.75

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 36.26

Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76

Selected major risk factors and global and regional burden of disease. Lancet (2002) 24.47

Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA (1991) 14.36

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 12.92

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension (2006) 11.68

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61

Clinical inertia. Ann Intern Med (2001) 11.14

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13

Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA (2003) 9.06

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (2003) 8.55

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA (1997) 5.91

Blood pressure and end-stage renal disease in men. N Engl J Med (1996) 5.68

Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA (1996) 5.63

Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension (2003) 5.63

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87

Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med (2009) 3.85

Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension (2009) 2.28

Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension (2008) 2.10

New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens (1996) 1.95

Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens (2007) 1.86

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther (2008) 1.69

Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med (2007) 1.69

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) (2001) 1.59

Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med (2004) 1.56

Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs (2005) 1.31

Hypertension Improvement Project (HIP): study protocol and implementation challenges. Trials (2009) 1.13

Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig (2009) 1.12

Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs (2008) 1.11

Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs (2008) 1.09

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs (1995) 1.09

Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig (2009) 0.99

Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) (2009) 0.93

Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich) (2006) 0.92

Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig (2009) 0.89

Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol (2009) 0.87

Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther (1997) 0.85

Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens (1999) 0.85

Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig (2009) 0.84

Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol (1995) 0.84

Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis (2010) 0.82

Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens (2007) 0.82

Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother (2009) 0.81

Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther (2005) 0.78

Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens (2010) 0.78

Pharmacological differences between calcium antagonists. Eur Heart J (1997) 0.78

Pharmacogenetics of antihypertensive drug response. Curr Hypertens Rep (2004) 0.77

The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm. Clin Exp Hypertens (2010) 0.76